6 research outputs found

    Use of anticoagulants and antiplatelet agents in stable outpatients with coronary artery disease and atrial fibrillation. International CLARIFY registry

    Get PDF

    FAST enough?:The U.K. general public's understanding of stroke

    No full text
    Good public awareness of stroke symptoms and the need for rapid admission to hospital can improve patient outcomes. However, evidence suggests that this awareness is currently inadequate. Therefore, it is important to identify gaps in public knowledge to target public health campaigns appropriately. This questionnaire study of 356 adults in Birmingham city centre assessed the general public's understanding of stroke, whether demographic factors affect this and the influence of a national campaign (FAST) on knowledge. The mean overall knowledge score was 11.8 out of 15; however, only 54.2% of those questioned knew that diabetes, hypertension and high cholesterol were stroke risk factors. Of those questioned, 60.2% were aware of the FAST campaign. General understanding of stroke was fairly good, although it was found to be worse in the youngest, oldest age and non-white groups. Although there was good awareness of the FAST campaign, many people did not know what the individual letters meant. Based on the results of our study, we conclude that it might take considerable time for public awareness campaigns to achieve their full impact

    Chronic coronary syndromes without standard modifiable cardiovascular risk factors and outcomes: the CLARIFY registry

    No full text
    Background and Aims: It has been reported that patients without standard modifiable cardiovascular (CV) risk factors (SMuRFs—diabetes, dyslipidaemia, hypertension, and smoking) presenting with first myocardial infarction (MI), especially women, have a higher in-hospital mortality than patients with risk factors, and possibly a lower long-term risk provided they survive the post-infarct period. This study aims to explore the long-term outcomes of SMuRF-less patients with stable coronary artery disease (CAD). Methods: CLARIFY is an observational cohort of 32 703 outpatients with stable CAD enrolled between 2009 and 2010 in 45 countries. The baseline characteristics and clinical outcomes of patients with and without SMuRFs were compared. The primary outcome was a composite of 5-year CV death or non-fatal MI. Secondary outcomes were 5-year all-cause mortality and major adverse cardiovascular events (MACE—CV death, non-fatal MI, or non-fatal stroke). Results: Among 22 132 patients with complete risk factor and outcome information, 977 (4.4%) were SMuRF-less. Age, sex, and time since CAD diagnosis were similar across groups. SMuRF-less patients had a lower 5-year rate of CV death or non-fatal MI (5.43% [95% CI 4.08–7.19] vs. 7.68% [95% CI 7.30–8.08], P = 0.012), all-cause mortality, and MACE. Similar results were found after adjustments. Clinical event rates increased steadily with the number of SMuRFs. The benefit of SMuRF-less status was particularly pronounced in women. Conclusions: SMuRF-less patients with stable CAD have a substantial but significantly lower 5-year rate of CV death or non-fatal MI than patients with risk factors. The risk of CV outcomes increases steadily with the number of risk factors
    corecore